- Home
- GOVX vs DLXY Comparison
GOVX vs DLXY Comparison
Compare GOVX & DLXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- DLXY
- Stock Information
- Founded
- GOVX 2001
- DLXY 2007
- Country
- GOVX United States
- DLXY Singapore
- Employees
- GOVX N/A
- DLXY N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- DLXY
- Sector
- GOVX Health Care
- DLXY
- Exchange
- GOVX Nasdaq
- DLXY Nasdaq
- Market Cap
- GOVX 16.8M
- DLXY 13.9M
- IPO Year
- GOVX N/A
- DLXY 2025
- Fundamental
- Price
- GOVX $0.60
- DLXY $0.91
- Analyst Decision
- GOVX Strong Buy
- DLXY
- Analyst Count
- GOVX 3
- DLXY 0
- Target Price
- GOVX $10.67
- DLXY N/A
- AVG Volume (30 Days)
- GOVX 1.2M
- DLXY 1.3M
- Earning Date
- GOVX 11-11-2025
- DLXY 11-13-2025
- Dividend Yield
- GOVX N/A
- DLXY N/A
- EPS Growth
- GOVX N/A
- DLXY N/A
- EPS
- GOVX N/A
- DLXY 0.07
- Revenue
- GOVX $6,143,044.00
- DLXY $314,916,000.00
- Revenue This Year
- GOVX N/A
- DLXY N/A
- Revenue Next Year
- GOVX N/A
- DLXY N/A
- P/E Ratio
- GOVX N/A
- DLXY $12.95
- Revenue Growth
- GOVX 1943.07
- DLXY 8.90
- 52 Week Low
- GOVX $0.43
- DLXY $0.64
- 52 Week High
- GOVX $3.88
- DLXY $7.16
- Technical
- Relative Strength Index (RSI)
- GOVX 47.47
- DLXY N/A
- Support Level
- GOVX $0.52
- DLXY N/A
- Resistance Level
- GOVX $0.62
- DLXY N/A
- Average True Range (ATR)
- GOVX 0.05
- DLXY 0.00
- MACD
- GOVX 0.01
- DLXY 0.00
- Stochastic Oscillator
- GOVX 71.36
- DLXY 0.00
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.